Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response (CRR) at 76 weeks compared to those treated with standard therapy alone. Safety was in line with the well-characterized profile of Gazyva. No new safety signals were identified.
"Gazyva achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term...
ログインすると全部閲覧できます。
ログイン
